INTRODUCTION
IgG4-related disease (IgG4-RD) is a recently recognized rare and novel systemic inflammatory disorder characterized by tumefactive lesions with infiltrating IgG4-positive plasma cells [1, 2] . IgG4-RD affects the pancreas, retroperitoneal, kidney, biliary tree, aorta, periorbital tissues, lung, meninges, salivary glands, lacrimal glands, and lymph nodes. The elevated serum concentration of IgG4 is closely associated with IgG4-RD. Recent studies have shown that B cell depletion therapy using rituximab (RTX) appears to be an effective and alternative approach in the treatment of refractory IgG4-RD [3] . These results also suggest that B cells may play critical roles in the disease process. However, the etiology of IgG4-RD and B cell biology in the disease have not been fully defined yet. To date, there are a few reports about B cell abnormality in the peripheral blood from patients with IgG4-RD. RP105 molecule (CD180), one of the toll-like receptor (TLR) associated molecules, is expressed on normal B cells [4, 5] and regulates activation of B cells. In normal persons, RP105-negative B cells are seldom (1.7±1.1%) [6] . Interestingly, in B cell activated diseases, such as systemic lupus erythematosus (SLE), dermatomyositis (DM) and Sjögren's syndrome (SS), the numbers of RP105-negative B cells increase [6, 7] . Especially, RP105-negative B cells produce autoantibodies and take part in pathophysiology of human SLE and lupus-prone (NZB NZW) F1 (NZBWF1) mouse [8] . Moreover, detailed analyses have suggested that the RP105-negative B cells are highly activated later B cells including plasmablasts and early plasma cells [9] . Therefore, we investigated the percentages of RP105-negative B cells in the peripheral blood from patients with IgG4-RD. The clinical images of four patients and representative profiles of Our results suggest that the RP105-negative B cells increase in IgG4-RD in which activation and dysregulation of B cells may be involved. Because RP105-negative B cells consist of mainly plasmablasts and early plasma cells, precursors of plasma cells may increase in the peripheral blood in IgG4-RD. It is also important to investigate the infiltrating RP105-negative B cells histologically. Moreover, the analyses of the relationship of the numbers of RP105-negative B cells with disease activity and severity of organ disorders may be required and we plan further studies.
However, serial analyses of the peripheral blood in two patients after treatment showed that RP105-negative B cells decreased in parallel with disease activity. In addition, interestingly, the percentages of serum level of IgG4 in total IgG may be associated with the percentages of RP105-negative B cells (%IgG4: %RP105-negative B cells, case 1. 28.3%: 18.8%, case 2. 20.3%: 27.9%, case 3. 12.3%: 8.3%, case 4. 25.7%: 27.5%). These facts suggest that RP105-negative B cells may be one of the possible sources of serum IgG4. Therefore, in IgG4-RD, RP105-negative B cells may be a possible therapeutic target.
We present four cases of IgG4-RD showing increased numbers of RP105-negative B cells. The numbers of RP105-negatvie B cells may be associated with disease activity in evaluated two cases. Analysis of expression of RP105 on B cells may be helpful in evaluation of the patients with IgG4-RD. However, its significance in pathophysiology of the disease is still open to further evaluation. 
